Nitric Oxide

Clinical Exposure and Safety Data for Nitric Oxide-Releasing Acne Topical Released

Clinical Exposure and Safety Data for Nitric Oxide-Releasing Acne Topical Released

Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, presented safety data for acne topical SB204 at the 23rd World Congress of Dermatology this month. The single center, double blind, randomized, two-period crossover study showed that, following topical application of nitric oxide-releasing SB204, there was no measurable systemic exposure in patients with acne vulgaris.

Novan Announces Positive Phase 2 Results for Novel Acne Treatment

Novan Therapeutics, a specialty pharmaceutical company focused on medical nitric oxide therapies has announced positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. The Phase 2 study was a double blind, vehicle-controlled, dose-ranging study conducted in 150 subjects with acne. Subject were randomized evenly to 1% SB204, 4% SB204, or vehicle gel and treated for 12 weeks. SB204 demonstrated good cutaneous tolerability with no reported serious adverse events.

Novan Awarded $7.8 Million Contract To Develop Thermal Burn Treatment

Burn patients may soon have a new treatment option available, as the U.S. Department of Health and Human Services has entered into a contract with Novan Therapeutics (www.novantherapeutics.com) to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, will provide funding of $7.8 million over two years.